(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 29 January 2004 (29.01.2004)

PCT

(10) International Publication Number WO 2004/009026 A3

- (51) International Patent Classification⁷: A61K 31/27, 31/66, 31/445, 31/195, 31/42, A61P 25/28
- (21) International Application Number:

PCT/US2003/022746

- (22) International Filing Date: 22 July 2003 (22.07.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/397,123

22 July 2002 (22.07.2002) US

- (71) Applicant (for all designated States except US): DUKE UNIVERSITY [US/US]; c/o Office of Science and Technology, M454 Davison Building, Duke University Medical Center, Durham, NC 27710 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): HELLER, James, H. [US/US]; 2427 Tilghman Circle, Chapel Hill, NC 27514 (US). KISHNANI, Priya [IN/US]; 6 Vinson, Place, Durham, NC 27705 (US). WORLEY, Gordon [US/US]; 408 Deming Road, Chaple Hill, NC 27514 (US).
- (74) Agent: KAGAN, Sarah, A.; BANNER & WITCOFF, LTD., 11th floor, 1001 G Street, NW, Washington, D. C. 20001.4597 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 15 July 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: CHOLINERGIC THERAPY FOR INDIVIDUALS WITH LEARNING DISABILITIES

(57) Abstract: Cholinergic agents are used to improve specific learning deficits and language function in individuals of normal intelligence. Psychosocial deficits including a pragmatics impairment, reading deficits, a problem solving impairment, an information processing impairment, an adaptive function impairment, social skills impairment, attention impairment, a mood impairment and employment skills impairment, can also be treated in this manner. The cholinergic treatments can be combined with more traditional educational, psychological, and behavioral therapies for enhanced therapeutic benefit.



INTERNATIONAL SEARCH REPORT

International application No.

| | | | PC1/US03/22746 | 1 |
|--|---|--|--|--|
| A. CLA | SSIFICATION OF SUBJECT MATTER | | | |
| IPC(7) US CL | : A61K 31/27, 31/66, 31/445, 31/195, 31/42; A | 61P 25/28 | | |
| | : 514/319; 380, 561 | | | |
| B. FIEL | International Patent Classification (IPC) or to both na DS SEARCHED | itional classification an | nd IPC | |
| | | | | |
| Minimum do | cumentation searched (classification system followed | by classification symbo | ols) | |
| 0.8. : 3 | 14/319; 380, 561 | | | |
| | | | | į |
| Documentati | on searched other than minimum documentation to the | extent that such docu | mente are included i | n the fields secrebed |
| | | BALL SEEL COOK | ments are mended t | i the fields searched |
| | | | | |
| | | | | |
| Electronic da | ta base consulted during the international search (nam ontinuation Sheet | e of data base and, wh | nere practicable, sear | rch terms used) |
| Please See C | onunuation Sheet | | | |
| | | | | |
| | UMENTS CONSIDERED TO BE RELEVANT | | | |
| Category * | Citation of document, with indication, where a | ppropriate, of the rele | vant passages | Relevant to claim No. |
| Y | EP 1203584 A1 (TROGNONI, MARIANO) 08 May | y 2002 (08.05.2002), e | entire reference | 1-14, 16-18, and 20-47 |
| | • | | | T, 10-10, and 20-7/ |
| Y | ALLAIN et al. Drugs and Language, Pharmacoling | uistics, EUR. NEURO | L. December 11. | 1-48 |
| 1/ | 2001 entire reference, especially pages 6-7. | | | |
| Y | US 5,847,155 A (FARACI et al) 08 December 1998 | 3 (08.12.1998), entire | reference. | 1-48 ′ |
| Y | WERED at al Donangeil Indused DEM Glass | | | |
| • | WEBER et al Donepezil-Induced REM Sleep Augm in Elderly, Healthy Persons, Exp. Gerontol. Februa | entation Enhances Mer | mory Performance | 1-48 |
| | i | ry 2001, Vol. 36. No. | 2, abstract. | |
| | l | | | |
| | | | | |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04 04 2002) | entire reference | 1.49 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| Y | US 2002/0040038 A1 (PRATT, RAYMOND) 04 A | pril 2002 (04.04.2002) |), entire reference. | 1-48 |
| | | | | 1-48 |
| Furthe | documents are listed in the continuation of Box C. | |), entire reference. | 1-48 |
| Furthe | | See patent | family annex. | mational filing date or priority |
| Further S "A" documen | documents are listed in the continuation of Box C. pecial categories of cited documents: | See patent "T" later docume date and not | family annex. ent published after the inte | mational filing date or priority |
| Further S | documents are listed in the continuation of Box C. | See patent "T" later docume date and not principle or | family annex. ent published after the inte in conflict with the applic theory underlying the inve | rnational filing date or priority ation but cited to understand the ntion |
| Further S'A" documen of particu | documents are listed in the continuation of Box C. pecial categories of cited documents: t defining the general state of the art which is not considered to be | See patent "T" later docume date and not principle or "X" document of | family annex. ent published after the inte in conflict with the applic theory underlying the invo | rnational filing date or priority atton but cited to understand the intion |
| Further S "A" documen of particu | documents are listed in the continuation of Box C. pecial categories of cited documents: I defining the general state of the art which is not considered to be lar relevance | See patent "T" later docume date and not principle or "X" document of considered n | family annex. ent published after the inte in conflict with the applic theory underlying the invo | rnational filing date or priority ation but cited to understand the ntion |
| Further S "A" documen of partice "E" earlier ap "L" documen establish | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as | See patent "T" later docume date and not principle or "X" document of considered n when the do | family annex. Int published after the interior in conflict with the application of the property of the proper | rnational filing date or priority atton but cited to understand the intion claimed invention cannot be red to involve an inventive step |
| Further S "A" document of particular ap "E" earlier ap | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as | "Y" See patent later docume date and not principle or "X" document of considered n when the do | family annex. In published after the interin conflict with the applic theory underlying the inversional particular relevance; the course or cannot be conside current is taken alone. I particular relevance; the o involve an inventive stering and the control of | rnational filing date or priority ation but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is |
| Further S "A" document of particular ap "L" document establish specified | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be lar relevance plication or patent published on or after the international filing date to the which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as | "Y" See patent "A" later docume date and not principle or "X" document of considered in when the document of considered to combined with the document of considered to consider | family annex. Introduction to make a conflict with the application theory underlying the involved or cannot be conside cument is taken alone of particular relevance; the oinvolve an inventive step the one or more other such than the confliction of the conflic | rnational filing date or priority ation but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be owhen the document is a document. |
| Further S "A" documen of particu "E" earlier ap "L" documen establish specified | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be alar relevance plication or patent published on or after the international filing date to the may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as | "Y" See patent "A" later docume date and not principle or "X" document of considered in when the document of considered to combined with the document of considered to consider | family annex. In published after the interin conflict with the applic theory underlying the inversional particular relevance; the course or cannot be conside current is taken alone. I particular relevance; the o involve an inventive stering and the control of | rnational filing date or priority ation but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be owhen the document is a document. |
| Further S "A" document of particular aprile april | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be lar relevance plication or patent published on or after the international filing date to the which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as | "Y" See patent "Attention of the state of t | family annex. Introduction to make a conflict with the application theory underlying the involved or cannot be conside cument is taken alone of particular relevance; the oinvolve an inventive step the one or more other such than the confliction of the conflic | rnational filing date or priority ation but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art |
| Further S "A" document of particular "E" earlier ap "L" document establish specified "O" document "P" document priority document | documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be alar relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as t referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the ate claimed | "T" later docume date and not principle or "X" document of considered in when the do "Y" document of considered to combined with being obvious "&" document many document d | family annex. Introduction to make a construction of the interior of the inte | rnational filing date or priority atton but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be owhen the document is documents, such combination e art |
| Further S A* documen of particu E* earlier ap L* documen establish specified O* documen P* documen priority do | defining the general state of the art which is not considered to be that relevance policiation or patent published on or after the international filling date to which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as a referring to an oral disclosure, use, exhibition or other means to published prior to the international filling date but later than the atte claimed crual completion of the international search | "Y" See patent "Attention of the state of t | family annex. Int published after the interior in conflict with the application of the particular relevance; the lovel or cannot be considecument is taken alone a particular relevance; the oinvolve an inventive step in the one or more other such as to a person skilled in the member of the same patent the international seame | rnational filing date or priority atton but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art |
| Further S "A" document of particular ap "L" document establish specified "O" document priority of Date of the a | r documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filling date to which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as to referring to an oral disclosure, use, exhibition or other means to published prior to the international filling date but later than the attendation of the international search 1004 (09.01.2004) | "T" later docume date and not principle or "X" document of considered in when the do "Y" document of considered to combined with being obvious "&" document many document d | family annex. Int published after the interior in conflict with the application of the particular relevance; the lovel or cannot be considecument is taken alone a particular relevance; the oinvolve an inventive step in the one or more other such as to a person skilled in the member of the same patent the international seame | rnational filing date or priority atton but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art |
| Further S "A" document of particular aprilem establish specified document priority of Date of the a consument of the accordance of the ac | r documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filing date to which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as to referring to an oral disclosure, use, exhibition or other means to published prior to the international filing date but later than the attendate claimed crual completion of the international search 004 (09.01.2004) ailing address of the ISA/US | "T" later docume date and not principle or "X" document of considered in when the do "Y" document of considered to combined with being obvious "&" document many document d | family annex. Int published after the interior in conflict with the application of the particular relevance; the lovel or cannot be considecument is taken alone a particular relevance; the oinvolve an inventive step in the one or more other such as to a person skilled in the member of the same patent the international seame | rnational filing date or priority atton but cited to understand the intion claimed invention cannot be red to involve an inventive step claimed invention cannot be owhen the document is documents, such combination e art |
| Further S "A" documen of particu "E" earlier ap "L" documen establish specified "O" documen "P" documen priority d Date of the a 09 January 2 Name and m | r documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filling date to which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as to referring to an oral disclosure, use, exhibition or other means to published prior to the international filling date but later than the fate claimed ctual completion of the international search 004 (09.01.2004) ailling address of the ISA/US il Stop PCT, Attn: ISA/US | See patent "T" later docume date and not principle or "X" document of considered in combined wi being obviou "&" document m Date of mailing of the | family annex. Int published after the interior in conflict with the application of the particular relevance; the lovel or cannot be conside cument is taken alone a particular relevance; the oinvolve an inventive step in the one or more other such as to a person skilled in the member of the same patent the international seame | rnational filing date or priority atton but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art |
| Further S "A" document of particular appropriate of the amount of the | r documents are listed in the continuation of Box C. pecial categories of cited documents: t defining the general state of the art which is not considered to be lar relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as t referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the late claimed ctual completion of the international search 004 (09.01.2004) ailing address of the ISA/US iii Stop PCT, Attn: ISA/US mmissioner for Patents | "Y" document of considered to combined with being obvious document of considered to combined with being obvious document of considered to combined with being obvious document must be seen to combine the combined with being obvious document must be seen to combine the combined with being obvious document must be seen to combine the combined with the com | family annex. Int published after the interior conflict with the application to conflict with the application of particular relevance; the considecument is taken alone In particular relevance; the considecument is taken alone In particular relevance; the converse in the considecument is taken alone In particular relevance; the converse in the c | rnational filing date or priority ation but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art family |
| Further S "A" document of particular ap "L" document establish specified of document priority of the at the second of the at the sec | r documents are listed in the continuation of Box C. pecial categories of cited documents: defining the general state of the art which is not considered to be that relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as the referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the ate claimed ctual completion of the international search 004 (09.01.2004) ailling address of the ISA/US minissioner for Patents b. Box 1450 | See patent "T" later docume date and not principle or "X" document of considered in combined wi being obviou "&" document m Date of mailing of the | family annex. Int published after the interior conflict with the application to conflict with the application of particular relevance; the considecument is taken alone In particular relevance; the considecument is taken alone In particular relevance; the converse in the considecument is taken alone In particular relevance; the converse in the c | rnational filing date or priority ation but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art family |
| Further S "A" document of particular application of particular applic | r documents are listed in the continuation of Box C. pecial categories of cited documents: t defining the general state of the art which is not considered to be lar relevance plication or patent published on or after the international filing date t which may throw doubts on priority claim(s) or which is cited to the publication date of another citation or other special reason (as t referring to an oral disclosure, use, exhibition or other means t published prior to the international filing date but later than the late claimed ctual completion of the international search 004 (09.01.2004) ailing address of the ISA/US iii Stop PCT, Attn: ISA/US mmissioner for Patents | "Y" document of considered in when the do combined with being obvious document of Considered for Considered to Combined with the document of Considered to Combined with being obvious document much that the combined with the comb | family annex. Int published after the interior conflict with the application to conflict with the application of particular relevance; the considecument is taken alone In particular relevance; the considecument is taken alone In particular relevance; the converse in the considecument is taken alone In particular relevance; the converse in the c | rnational filing date or priority ation but cited to understand the ention claimed invention cannot be red to involve an inventive step claimed invention cannot be to when the document is a documents, such combination e art family Ch report 2004 |

| | PCT/US03/22746 |
|--|--|
| INTERNATIONAL SEARCH REPORT | |
| | |
| | |
| | |
| | |
| | |
| | |
| | • |
| | |
| | |
| · | |
| | |
| | |
| | |
| Continuation of B. FIELDS SEARCHED Item 3: | |
| Electronic Data Bases Searched: EAST, PALM, Registry, Medline, CA, CAPI | US, USPATFULL, DRUGU |
| Search Terms: Donepezil, 1,2,3,4-tetrahydro-9-Acridinamine, 9-amino-1,2,3,4-1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, and language | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |
| 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydro-9-aminoacridine, 9-Am Tetrahydroaminacrine, Tetrahydroaminocrine, THA, "El Galanthamine, BRN 0093736, Galantamin, Galantamina, Galantamine, Jilkon, 1 | ino-1,2,3,4-tetrahydroacridine, Tacrine, NA 713 free base, Exelon, Rivastigmine, SDZ 212-713. |